Is TB-500 the same as thymosin beta-4?

TB-500 is the synthetic 17-amino-acid active fragment of thymosin beta-4. The full thymosin beta-4 protein is 43 amino acids. Research literature uses both names sometimes interchangeably, but TB-500 is the commercially available research peptide.

What does TB-500 actually do at the molecular level?

TB-500/Tβ4 binds and sequesters G-actin, preventing premature polymerisation. This regulates cell motility, drives angiogenesis via VEGF upregulation, and accelerates wound healing (Goldstein 2005).

Are there human TB-500 clinical trials?

Yes — Crockford 2010 (cardiac repair trial, post-MI) and Sosne 2010 (corneal wound healing) are the most-cited human studies. Both used IV thymosin beta-4 at clinical doses.

TB-500 / Thymosin Beta-4: Complete UAE Research Deep Dive 2026

Published 23 June 2026 · REVIVE Peptides Research Desk · 10 min read

TL;DR. TB-500 is the 17-amino-acid active fragment of thymosin beta-4 (Tβ4). It binds G-actin to regulate cell motility, drives VEGF-mediated angiogenesis, and accelerates wound healing across cardiac, corneal, dermal, and tendon models. Human RCT data exists in cardiac (Crockford 2010) and corneal (Sosne 2010) contexts; musculoskeletal use is animal-research-led.

What Is Thymosin Beta-4?

Thymosin beta-4 (Tβ4) is a 43-amino-acid intracellular protein, ubiquitous across mammalian tissues. It is the primary actin-sequestering molecule in human cells — by binding monomeric G-actin and preventing premature polymerisation, it controls when and where cells extend, divide, and migrate.

"TB-500" refers to a synthetic 17-amino-acid fragment containing the active actin-binding region of Tβ4. In research literature the names are used somewhat interchangeably, but commercially the term TB-500 refers to the fragment supplied for research use.

Mechanism of Action

Action	How it works	Reference
Actin sequestration	Binds G-actin 1:1, regulates polymerisation	Safer 1991
Angiogenesis	Upregulates VEGF, promotes endothelial migration	Grant 1999
Anti-inflammatory	Suppresses NF-κB pathway	Sosne 2007
Stem cell recruitment	Mobilises progenitor cells to injury sites	Smart 2007
Anti-apoptotic	Protects cells from ischemic death	Bock-Marquette 2004

Key Clinical Trials

Crockford 2010 — Cardiac Repair Post-MI

Crockford et al. 2010 reviewed thymosin beta-4 cardiac trials, including phase 1 work in post-myocardial-infarction patients. IV Tβ4 at 42, 140, or 420 mg single doses showed acceptable safety; phase 2 cardiac repair trials followed. Animal model work (Bock-Marquette 2004) had previously shown Tβ4 could activate epicardial progenitor cells to regenerate heart muscle.

Sosne 2010 — Corneal Wound Healing

Sosne et al. tested topical Tβ4 (0.1% solution) for corneal wound healing in human patients. Results showed accelerated re-epithelialisation vs vehicle. The corneal indication remains one of the most clinically advanced Tβ4 applications.

Goldstein 2005 — The Mechanism Foundation

Goldstein's 2005 review consolidated the wound-healing mechanism work in animals — diabetic skin wounds, corneal burns, cardiac ischemia — showing consistent acceleration of healing across tissue types.

What Research Doses Look Like

Application	Typical research dose	Frequency
General healing research	2–5 mg SC weekly	Loading 4 weeks, then taper
Tendon/ligament protocols	5 mg SC twice weekly	4–6 weeks
Topical corneal (Sosne 2010)	0.1% solution drops	4x daily
IV cardiac trials (Crockford)	42–420 mg single dose	Phase 1 dose-finding

REVIVE supplies TB-500 as 5 mg vials. See our reconstitution calculator for the math.

TB-500 vs BPC-157 — Different Tools

The two peptides are often stacked or compared. The differences:

Property	TB-500	BPC-157
Primary mechanism	Actin sequestration + angiogenesis	Cytoprotection + angiogenesis (VEGFR2)
Best evidence for	Cardiac repair, corneal healing	GI tract, tendon, muscle
Human RCTs published	Yes (cardiac, corneal)	None published
Half-life	Long (days)	Short (hours)
Frequency	Weekly or twice-weekly	Daily

See our dedicated comparison: BPC-157 vs TB-500.

Researching TB-500 in the UAE?
REVIVE supplies TB-500 5 mg vials with HPLC certificates and cold-chain delivery.
View TB-500 vials →

What's Still Missing

No published musculoskeletal RCTs. Despite widespread research use for tendon/ligament repair, peer-reviewed human trials in that indication don't exist.
Cancer concerns remain theoretical. Because Tβ4 upregulates VEGF and angiogenesis, theoretical concern exists about pro-tumour effects. Goldstein 2017 reviewed this and concluded current evidence does not support a cancer risk in healthy tissue, but the question stays open.
Optimal dose and frequency are not standardised. Research protocols vary widely.

Research use only. TB-500 supplied by REVIVE is labelled and sold strictly for in-vitro and research purposes — not for human consumption.

References

Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421–429.
Crockford D, Turjman N, Allan C, Angel J. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci. 2010;1194:179–189.
Sosne G, Qiu P, Christopherson PL, Wheater MK. Thymosin beta 4 suppression of corneal NFκB: a potential anti-inflammatory pathway. Exp Eye Res. 2007;84(4):663–669.
Bock-Marquette I, Saxena A, White MD, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466–472.
Smart N, Risebro CA, Melville AA, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177–182.